Last reviewed · How we verify
MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg (MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg) — The University of Queensland.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg TARGET | MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg | The University of Queensland | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg CI watch — RSS
- MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg CI watch — Atom
- MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg CI watch — JSON
- MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg alone — RSS
Cite this brief
Drug Landscape (2026). MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg — Competitive Intelligence Brief. https://druglandscape.com/ci/mf59-adjuvanted-sars-cov-2-sclamp-vaccine-5mcg. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab